Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Rapid Assessment of Cardiac Markers for the Evaluation of Acute Coronary Syndrome (RACE-ACS)

09:06 EDT 24th April 2014 | BioPortfolio

Summary

This clinical trial is being conducted to 1) evaluate the possible usefulness of a panel of cardiac markers in assessing emergency department patients with possible acute coronary syndrome, 2) evaluate the usefulness of BNP in assessing emergency department patients with possible acute coronary syndrome, 3) determine if BNP can be used to predict adverse events during hospitalization and in the emergency department, and 4) evaluate how a Point-of-Care testing platform affects resource utilization in the emergency department.

Description

The correct diagnosis of acute coronary syndrome (ACS) remains a frequent significant challenge for emergency physicians. Over eight million chest pain patients present annually and despite promising advances in diagnosis, over four percent of ACS patients are mistakenly discharged home. While the history and physical, cardiac risk factor assessment, ECG, and cardiac marker determination are all included in the assessment and risk stratification of patients presenting with possible ACS, this assessment is clearly far from perfect. Improved rapid and accurate means of assessment in this population in the ED are clearly needed.ED patients with chest discomfort will be screened and approached for study enrollment. Consenting patients meeting the study inclusion and exclusion criteria will be enrolled. Point-of-care serial cardiac marker measurements will be performed. Based on a web-based computerized randomization system, half (50%) the patients willundergo routine central laboratory testing only. Half (50%) of the patients will undergopoint-of-care markers performed in the ED in addition to routine central laboratory testing.In this second group, central laboratory test results will be blinded from the ED physicianuntil the disposition time. BNP will be blinded and not reported to physicians for the first 500 patients (Phase I). After the first 500 patients have been enrolled, an interim analysis will be performed to determine the clinical utility of BNP in patient assessment. After physician education of these results, the trial will resume for the remaining 500 patients (Phase II). In Phase II, BNP levels will be provided to the physicians using the same time and randomization format.The patients and their medical records will be followed for a period of thirty days and sixmonths after enrollment.

Study Design

Allocation: Randomized, Control: Active Control, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic

Conditions

Acute Coronary Syndrome

Intervention

Triage CardioProfilER (Troponin I, Myoglobin, CK-MB, BNP)

Location

UC Davis Medical Center
Sacramento
California
United States
95817

Status

Terminated

Source

Biosite

Results (where available)

View Results

Links

Medical and Biotech [MESH] Definitions

One of the three polypeptide chains that make up the TROPONIN complex. It is a cardiac-specific protein that binds to TROPOMYOSIN. It is released from damaged or injured heart muscle cells (MYOCYTES, CARDIAC). Defects in the gene encoding troponin T result in FAMILIAL HYPERTROPHIC CARDIOMYOPATHY.

One of the three polypeptide chains that make up the TROPONIN complex. It inhibits F-actin-myosin interactions.

One of the three polypeptide chains that make up the TROPONIN complex of skeletal muscle. It is a calcium-binding protein.

Abnormal balloon- or sac-like dilatation in the wall of CORONARY VESSELS. Most coronary aneurysms are due to CORONARY ATHEROSCLEROSIS, and the rest are due to inflammatory diseases, such as KAWASAKI DISEASE.

An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode but that does not usually result in MYOCARDIAL INFARCTION.

Clinical Trials [1416 Associated Clinical Trials listed on BioPortfolio]

Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndrome (ACS)

Release of troponin evaluated by the peak of troponin during the hospital phase.Because of its sensitivity and specificity as well as its widespread use in routine practice, rise in tropo...

TnThs for Identification Myocardial Infarction

OBJECTIVES/BACKGROUND: We sought to determine the early diagnostic value of the new high sensitive cardiac troponin T assay (TnThs) in suspected acute coronary syndrome (ACS) and to compar...

Randomized Trial of Prehospital Tropin Levels in Acute Coronary Syndrome (ACS)

This study randomizes patients seen by Redmond Medic One into a control arm and a study arm when they present with acute coronary syndrome and have non-contributory ECG's (i.e.non-STEMI)....

Same-Day Discharge After Coronary Percutaneous Transluminal Coronary Angioplasty (PTCA)

Same day discharge is safe and feasible in selected troponin negative patients undergoing coronary planned percutaneous coronary intervention (PCI) or ad hoc PCI via the transfemoral appro...

Evaluation of Serial Troponin and Cardiac Multimarkers at the Point of Care in the Emergency Department

This is a multi-center study to assess the diagnostic accuracy of the Troponin I assay in the Biosite Triage Cardio3 Panel at the point-of-care (POC) in adults presenting to the emergency...

PubMed Articles [9747 Associated PubMed Articles listed on BioPortfolio]

Outcomes of non-acute coronary syndrome patients discharged from the emergency department with troponin positivity.

ABSTRACTBackground:Cardiac troponin elevation portends a worse prognosis in diverse patient populations. The significance of troponin elevation in patients discharged from emergency departments (EDs)...

Cardiac troponin I in non- acute coronary syndrome patients with chronic kidney disease.

The aim of this study was to assess the results of troponin I (cTnI) in non- acute Coronary Syndrome (ACS) patients with chronic kidney disease (CKD). We also examined the risk factors for elevated cT...

Risk stratification and timing of coronary angiography in acute coronary syndromes: are we targeting the right patients in a timely manner? (ANZACS-QI 1).

The New Zealand non-ST elevation acute coronary syndrome (NSTEACS) guideline recommends that clinically appropriate patients with combined high risk features (positive troponin and ischaemic ECG and a...

Clinical Inquiry: When you suspect ACS, which serologic marker is best?

Measurement of troponin levels provides the most sensitive and accurate serologic information in evaluating a patient with acute coronary syndrome (ACS); troponin elevations are more sensitive than el...

Biomarkers and acute coronary syndromes: an update.

Biomarkers complement clinical assessment and the 12-lead ECG in the diagnosis, risk stratification, triage, and management of patients with suspected acute coronary syndrome (ACS). While there is bro...

More From BioPortfolio on "Rapid Assessment of Cardiac Markers for the Evaluation of Acute Coronary Syndrome (RACE-ACS)"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Trial